Bone Biologics Corporation to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Bone Biologics (Nasdaq: BBLG), a developer of orthobiologic products for spine fusion markets, has announced its participation in the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Management is available throughout the conference for virtual one-on-one meetings. Institutional investors and industry professionals can register to attend the conference virtually or in-person at the Lotte New York Palace Hotel.
About Bone Biologics
Bone Biologics was founded to pursue regenerative medicine for bone. The Company is undertaking work with select strategic partners that builds on the preclinical research of the Nell-1 protein. Bone Biologics is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240904108361/en/
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
Kgolodetz@lhai.com
Source: Bone Biologics Corporation